[go: up one dir, main page]

WO2001044269B1 - Brain protein markers - Google Patents

Brain protein markers

Info

Publication number
WO2001044269B1
WO2001044269B1 PCT/US2000/033903 US0033903W WO0144269B1 WO 2001044269 B1 WO2001044269 B1 WO 2001044269B1 US 0033903 W US0033903 W US 0033903W WO 0144269 B1 WO0144269 B1 WO 0144269B1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
page
lines
new
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/033903
Other languages
French (fr)
Other versions
WO2001044269A9 (en
WO2001044269A3 (en
WO2001044269A2 (en
Inventor
Nancy Johnston-Wilson
Christina Sims
Jean-Paul Hofmann
N Leigh Anderson
Andrew Shore
Robert Yolken
E Fuller Torrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Large Scale Proteomics Corp
Original Assignee
Johns Hopkins University
Large Scale Proteomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Large Scale Proteomics Corp filed Critical Johns Hopkins University
Priority to AU25794/01A priority Critical patent/AU2579401A/en
Publication of WO2001044269A2 publication Critical patent/WO2001044269A2/en
Publication of WO2001044269A3 publication Critical patent/WO2001044269A3/en
Publication of WO2001044269B1 publication Critical patent/WO2001044269B1/en
Publication of WO2001044269A9 publication Critical patent/WO2001044269A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Protein markers for various psychiatric and neurological disorders were discovered. Diagnostic assays for these conditions were based on the levels of individual or combinations. The markers are targets or drug discovery for therapeutic and prophylactic uses.

Claims

AMENDED CLAIMS
[received by the International Bureau on 17 September 2001 ( 17.09.01), original claims 5 and 6 amended; new claims 10-15 added, remaining claims unchanged (2 pages)]
products produced by said proteins in said Biological sample, and
Comparing the result to standard amounts found in standardized biological samples.
5. The method of claim 4 wherein the protein is selected from the group consisting of the proteins listed in Table 2.
6. The method of claim 1 or 4 wherein the protein is selected form the group consisting of the proteins listed in Figure 7.
7. A pharmaceutical composition comprising an effective amount of a protein having abnormal levels in an individual with a brain disorder and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising an effective amount of a nucleic acid encoding a protein having abnormal levels in an individual with a brain disorder and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 7 or 8 wherein the pharmaceutical composition is encapsulated in a liposome or micele.
10. The method of claim 1 or 4 wherein the brain disorder is a psychiatric disorder.
36
11. The method of claim 10 wherein the psychiatric disorder is schizophrenia, major depression or bipolar disease.
12. The method of claim l or 4 wherein the protein is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO : 2, SEQ ID NO : 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 , SEQ ID NO; 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.
13. The method of claim 12, wherein said protein comprises a postranslational modification.
14. The compositions of claims 7 or 8 , wherein said brain disorder is a psychiatric disorder.
15. The composition of claim 14, wherein said psychiatric disorder is schizophrenia, major depression or bipolar disorder.
STATEMENT UNDER ARTICLE 19
1.1 Claim 5 has been amended to change the dependency from claim 1 to claim 4.
1.2 Claim 6 has been amended to change the dependency from claim 1 to claim 1 or 4.
1.3 Claim 10 is a new claim which finds support on page 5, lines 4-11 and throughout the description.
1.4 Claim 11 is a new claim which finds support on page 5, lines 4-11 and throughout the description.
1.5 Claim 12 is a new claim which finds support in the Sequence Listing filed on 12 July 2001 in response to an Invitation to Furnish Nucleotide and/or Amino Acid Sequence Listing Complying with Standard dated 13 April 2001.
1.6 Claim 13 is a new claim which finds support on page 9, lines 9-19.
1.7 Claim 14 is a new claim which finds support on page 5, lines 4-11 and page 15, lines 11- 22.
1.8 Claim 15 is a new claim which finds support on page 5, lines 4-11 and page 15, lines 11- 22.
38
PCT/US2000/033903 1999-12-17 2000-12-15 Brain protein markers Ceased WO2001044269A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25794/01A AU2579401A (en) 1999-12-17 2000-12-15 Brain protein markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17228699P 1999-12-17 1999-12-17
US60/172,286 1999-12-17

Publications (4)

Publication Number Publication Date
WO2001044269A2 WO2001044269A2 (en) 2001-06-21
WO2001044269A3 WO2001044269A3 (en) 2001-12-13
WO2001044269B1 true WO2001044269B1 (en) 2002-01-10
WO2001044269A9 WO2001044269A9 (en) 2002-05-23

Family

ID=22627065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033903 Ceased WO2001044269A2 (en) 1999-12-17 2000-12-15 Brain protein markers

Country Status (2)

Country Link
AU (1) AU2579401A (en)
WO (1) WO2001044269A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7236888B2 (en) 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6937330B2 (en) 1999-04-23 2005-08-30 Ppd Biomarker Discovery Sciences, Llc Disposable optical cuvette cartridge with low fluorescence material
US6687395B1 (en) 1999-07-21 2004-02-03 Surromed, Inc. System for microvolume laser scanning cytometry
AU2002217839A1 (en) * 2000-11-22 2002-06-03 The Regents Of The University Of California A method to measure the activation state of signaling pathways in cells
US6787761B2 (en) 2000-11-27 2004-09-07 Surromed, Inc. Median filter for liquid chromatography-mass spectrometry data
US7691645B2 (en) * 2001-01-09 2010-04-06 Agilent Technologies, Inc. Immunosubtraction method
US8068987B2 (en) * 2001-08-13 2011-11-29 Bg Medicine, Inc. Method and system for profiling biological systems
US6873915B2 (en) 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
US6989100B2 (en) 2002-05-09 2006-01-24 Ppd Biomarker Discovery Sciences, Llc Methods for time-alignment of liquid chromatography-mass spectrometry data
US7248360B2 (en) 2004-04-02 2007-07-24 Ppd Biomarker Discovery Sciences, Llc Polychronic laser scanning system and method of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JPH06507782A (en) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド Non-human recombinant mammals exhibiting amyloid formation symptoms of Alzheimer's disease

Also Published As

Publication number Publication date
WO2001044269A9 (en) 2002-05-23
AU2579401A (en) 2001-06-25
WO2001044269A3 (en) 2001-12-13
WO2001044269A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
WO2001044269B1 (en) Brain protein markers
WO1995021919A3 (en) Protein having tpo activity
EP1717315A3 (en) Osteoprotegerin binding proteins and receptors
WO2003020932A1 (en) Novel secretory proteins and dna thereof
CA2295999A1 (en) Nik proteins, nucleic acids and methods
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
CA2079454A1 (en) Steroid 5.alpha.-reductases
CA2280290A1 (en) Netrin receptors
JP2001520037A5 (en)
Butler The identity of a hydroxylamine-sensitive bond in the α1 chain of rat skin collagen
Sung et al. Human erythrocyte protein 4.2: isoform expression, differential splicing, and chromosomal assignment
EP1258494A1 (en) Multiprotein complexes from eukaryotes
AU8649698A (en) Cell cycle-regulating proteins
AU4136797A (en) Novel semaphorin gene: semaphorin y
WO2000078956A8 (en) Novel pyrrhocoricin-derived peptides, and methods of use thereof
DE69434118D1 (en) CLONING AND RECOMBINANT PRODUCTION OF THE CRF RECEPTOR (CRF = CORTICOTROPIN RELEASE FACTOR)
CA2225450A1 (en) Interleukin-1 receptor-associated protein kinase and assays
TW480285B (en) Enzyme for converting a precursor of a polypeptide into the active form that induces IFN-γ production, the process therefor, and the uses thereof
AR013801A1 (en) NEW MOLECULES OF ISOLATED NUCLEIC ACID, A HYDROLASSE HYDROLASSE EPOXIDE PROTEIN OF ISOLATED HEMATOPHAGO ART, A FORMULATION OF PULGE HYDROLASSE DEEPOXIDE PROTEINS, A THERAPEUTIC COMPOSITION THAT REDUCES HOSPITAL INFRASTAGATION; USE OF SUCH COMPOSITION FOR
WO1992011367A3 (en) Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof
Tsuda et al. Detection of a new mutant α-1-antichymotrypsin in patients with occlusive-cerebrovascular disease
ATE332974T1 (en) IL-1/TNF-ALPHA-ACTIVATED KINASE (ITAK), AND METHOD FOR THE PRODUCTION AND USE THEREOF
Donate et al. Characterization of an RNA-binding domain in the bacteriophage phi 29 connector.
Colin et al. Characterization of a new erythroid/megakaryocyte-specific nuclear factor that binds the promoter of the housekeeping human glycophorin C gene.
CA2180957A1 (en) Cloning and recombinant production of crf receptor(s)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP